CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

Blood - Tập 95 - Trang 1502-1505 - 2000
Ingrid Kuehnle1, M. Helen Huls1, Zhensheng Liu1, Micah Semmelmann1, Robert A. Krance1, Malcolm K. Brenner1, Cliona M. Rooney1, Helen E. Heslop1
1From the Center for Cell and Gene Therapy and Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.

Tóm tắt

After bone marrow transplantation (BMT) using T-cell–depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-specific cytotoxic T lymphocytes (CTL) is effective prophylaxis and treatment for this complication, and we routinely generate CTL for high-risk patients. However, EBV lymphoma can occur in recipients of matched-sibling transplants for whom CTL are unavailable or in patients for whom CTL administration is contraindicated. We report on 3 such patients, who were successfully and safely treated with rituximab, a CD20 monoclonal antibody. The patients remain disease free 7, 8, and 9 months, respectively, after therapy. We conclude that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT.

Tài liệu tham khảo

Heslop, 1997, Adoptive immunotherapy of EBV lymphoproliferative diseases., Immunol Rev., 157, 217, 10.1111/j.1600-065X.1997.tb00984.x O'Reilly, 1997, Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts., Immunol Rev., 157, 195, 10.1111/j.1600-065X.1997.tb00983.x Lucas, 1998, Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation., Blood., 91, 3654, 10.1182/blood.V91.10.3654 Gerritsen, 1996, Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children., Bone Marrow Transplant., 18, 377 Papadopoulos, 1994, Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation., N Engl J Med., 330, 1185, 10.1056/NEJM199404283301703 Heslop, 1994, Donor T cells to treat EBV-associated lymphoma., N Engl J Med., 331, 679, 10.1056/NEJM199409083311017 Rooney, 1995, Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation., Lancet., 345, 9, 10.1016/S0140-6736(95)91150-2 Heslop, 1996, Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes., Nature Med., 2, 551, 10.1038/nm0596-551 Rooney, 1998, Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients., Blood., 92, 1549, 10.1182/blood.V92.5.1549 Yee, 1997, Prospects for adoptive T cell therapy., Curr Opin Immunol., 9, 702, 10.1016/S0952-7915(97)80052-0 Gottschalk, 1998, Mutation in EBV produces immunoblastic lymphoma unresponsive to CTL immunotherapy [abstract]., Blood., 92(suppl 1), 321a Fischer, 1991, Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation., N Engl J Med., 324, 1451, 10.1056/NEJM199105233242102 Mahmoud, 1993, Anti-CD21 and CD24 monoclonal antibodies (Anti-CD21/24) for B-cell lymphoproliferative disease (LPD) following bone marrow transplantation (BMT) [abstract]., Blood., 82(suppl 1), 636a Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma., Blood., 90, 2188, 10.1182/blood.V90.6.2188 Leget, 1998, Use of rituximab, the new FDA-approved antibody., Curr Opin Oncol., 10, 548, 10.1097/00001622-199811000-00012 Hongeng, 1997, Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia., Lancet., 350, 767, 10.1016/S0140-6736(97)03098-5 Rooney, 1995, Early identification of Epstein-Barr virus-associated post-transplant lymphoproliferative disease., Br J Haematol., 89, 98, 10.1111/j.1365-2141.1995.tb08904.x Heslop, 1994, Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts., Hum Gene Ther., 5, 381, 10.1089/hum.1994.5.3-381 Faye, 1998, Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders., Lancet., 352, 1285, 10.1016/S0140-6736(05)70493-1 Davis, 1999, Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression., Clin Cancer Res., 5, 611 Hale, 1998, Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants., Blood., 91, 3079, 10.1182/blood.V91.8.3079.3079_3079_3083 Gross, 1999, B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome., Bone Marrow Transplant., 23, 251, 10.1038/sj.bmt.1701554 Cavazzana-Calvo, 1998, Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation., Br J Haematol., 103, 543, 10.1046/j.1365-2141.1998.00972.x
Thông tin
Thông tin xuất bản

Blood

Tập 95

1502-1505

Thông tin tác giả